157 related articles for article (PubMed ID: 34457038)
1. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.
Mora JS; Bradley WG; Chaverri D; Hernández-Barral M; Mascias J; Gamez J; Gargiulo-Monachelli GM; Moussy A; Mansfield CD; Hermine O; Ludolph AC
Ther Adv Neurol Disord; 2021; 14():17562864211030365. PubMed ID: 34457038
[TBL] [Abstract][Full Text] [Related]
2. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
Mora JS; Genge A; Chio A; Estol CJ; Chaverri D; Hernández M; Marín S; Mascias J; Rodriguez GE; Povedano M; Paipa A; Dominguez R; Gamez J; Salvado M; Lunetta C; Ballario C; Riva N; Mandrioli J; Moussy A; Kinet JP; Auclair C; Dubreuil P; Arnold V; Mansfield CD; Hermine O;
Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):5-14. PubMed ID: 31280619
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Vermersch P; Benrabah R; Schmidt N; Zéphir H; Clavelou P; Vongsouthi C; Dubreuil P; Moussy A; Hermine O
BMC Neurol; 2012 Jun; 12():36. PubMed ID: 22691628
[TBL] [Abstract][Full Text] [Related]
7. The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation.
Lo Coco D; Marchese S; La Bella V; Piccoli T; Lo Coco A
Chest; 2007 Jul; 132(1):64-9. PubMed ID: 17475635
[TBL] [Abstract][Full Text] [Related]
8. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
9. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis.
Trias E; Ibarburu S; Barreto-Núñez R; Babdor J; Maciel TT; Guillo M; Gros L; Dubreuil P; Díaz-Amarilla P; Cassina P; Martínez-Palma L; Moura IC; Beckman JS; Hermine O; Barbeito L
J Neuroinflammation; 2016 Jul; 13(1):177. PubMed ID: 27400786
[TBL] [Abstract][Full Text] [Related]
10. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.
Tramacere I; Dalla Bella E; Chiò A; Mora G; Filippini G; Lauria G;
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1180-5. PubMed ID: 25886781
[TBL] [Abstract][Full Text] [Related]
11. In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis.
Schuster J; Dreyhaupt J; Mönkemöller K; Dupuis L; Dieterlé S; Weishaupt JH; Kassubek J; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Johannesen S; Göricke B; Witzel S; Dorst J; Ludolph AC;
Eur J Neurol; 2024 Apr; 31(4):e16204. PubMed ID: 38240416
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
Gordon PH; Moore DH; Miller RG; Florence JM; Verheijde JL; Doorish C; Hilton JF; Spitalny GM; MacArthur RB; Mitsumoto H; Neville HE; Boylan K; Mozaffar T; Belsh JM; Ravits J; Bedlack RS; Graves MC; McCluskey LF; Barohn RJ; Tandan R;
Lancet Neurol; 2007 Dec; 6(12):1045-53. PubMed ID: 17980667
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy.
Mandrioli J; Biguzzi S; Guidi C; Sette E; Terlizzi E; Ravasio A; Casmiro M; Salvi F; Liguori R; Rizzi R; Pietrini V; Borghi A; Rinaldi R; Fini N; Chierici E; Santangelo M; Granieri E; Mussuto V; De Pasqua S; Georgoulopoulou E; Fasano A; ; Ferro S; D'Alessandro R
Neurol Sci; 2015 Dec; 36(12):2243-52. PubMed ID: 26205535
[TBL] [Abstract][Full Text] [Related]
14. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
[TBL] [Abstract][Full Text] [Related]
15. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
16. [Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].
Liu XX; Fan DS; Zhang J; Zhang S; Zheng JY
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(35):2472-5. PubMed ID: 20137433
[TBL] [Abstract][Full Text] [Related]
17. The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial.
Oki R; Izumi Y; Nodera H; Sato Y; Nokihara H; Kanai K; Sonoo M; Urushitani M; Nishinaka K; Atsuta N; Kohara N; Shimizu T; Kikuchi H; Oda M; Ikeda K; Nagai M; Komai K; Kojima Y; Kuzume D; Isose S; Shimohama S; Abe K; Ito H; Noda K; Ishihara T; Morita M; Shimohata T; Teramukai S; Kagimura T; Noma K; Yanagawa H; Kuwabara S; Kaji R;
JMIR Res Protoc; 2018 Dec; 7(12):e12046. PubMed ID: 30578206
[TBL] [Abstract][Full Text] [Related]
18. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Piette F; Belmin J; Vincent H; Schmidt N; Pariel S; Verny M; Marquis C; Mely J; Hugonot-Diener L; Kinet JP; Dubreuil P; Moussy A; Hermine O
Alzheimers Res Ther; 2011 Apr; 3(2):16. PubMed ID: 21504563
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
Cudkowicz ME; Titus S; Kearney M; Yu H; Sherman A; Schoenfeld D; Hayden D; Shui A; Brooks B; Conwit R; Felsenstein D; Greenblatt DJ; Keroack M; Kissel JT; Miller R; Rosenfeld J; Rothstein JD; Simpson E; Tolkoff-Rubin N; Zinman L; Shefner JM;
Lancet Neurol; 2014 Nov; 13(11):1083-1091. PubMed ID: 25297012
[TBL] [Abstract][Full Text] [Related]
20. Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.
He R; Zheng M; Lian L; Yao X
Cells; 2021 May; 10(5):. PubMed ID: 34067647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
